Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 3141Skin Neoplasms 554Lymphoma, T-Cell, Cutaneous 543Carcinoma, Non-Small-Cell Lung 421Neoplasms 388Mycosis Fungoides 369Breast Neoplasms 364Carcinoma, Basal Cell 360Keratosis, Actinic 335Sezary Syndrome 331Lymphoma, Non-Hodgkin 312Carcinoma, Renal Cell 308Neoplasm Metastasis 304Lymphoma 300Leukemia, Lymphocytic, Chronic, B-Cell 292Lymphoma, Large B-Cell, Diffuse 287Lymphoma, Follicular 286Hodgkin Disease 275Uveal Melanoma 274Lymphoma, B-Cell, Marginal Zone 273Lymphoma, Mantle-Cell 272Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Burkitt Lymphoma 258Lymphoma, Large-Cell, Immunoblastic 248Lung Neoplasms 236Colorectal Neoplasms 232Ovarian Neoplasms 214Lymphoma, Large-Cell, Anaplastic 206Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 203Multiple Myeloma 199

Interventions

talimogene laherparepvec 1Specimen Handling 1Nivolumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basosquamous × Dermatologic × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡